Tendinitis Treatment Industry Market Size

The Americas & Europe market for tendinitis treatment is expected to reach USD 19,582.95 Million by 2030 at 3.5% CAGR during the forecast period 2022-2030. Tendinitis is the inflammation of the tendon, thick cords that attache the muscles to the bone. The inflammation occurs as a result of sudden injury to the tendon, repetitive movement or disease condition such as diabetes, rheumatoid arthritis, gout, Reiter's syndrome or lupus. In case of patients with gout, the uric acid crystals appear in the tendon sheath leading to friction. Tendinitis is found to be prevalent among athletes and is one of the common sport injuries in sport players, especially tennis, golf and others. Various pharmacological and non-pharmacological treatments are available for the treatment of tendinitis. Non-Steroidal Anti-inflammatory Drugs (NSAIDs) constitute the preliminary treatment options. Other treatments including physical therapy, rest, and occupational therapy. Surgery is the last resort for tendinitis, and is only recommended in case of severe damage to the tendon that cannot be treated using pharmacological treatment options.

The market for tendinitis treatment is expected to grow at an exponential rate owing to increasing prevalence of sports injuries, rising geriatric population, increasing prevalence of patients suffering from diabetes and rheumatoid arthritis. Side effects of the treatment i.e. use of NSAIDs leading to stomach upset, and Gastrointestinal (GI) bleeding.

FIGURE 1: Americas & Europe Tendinitis Treatment Market by Region, 2016 (%)

Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation

Intended Audience

• Tendinitis Treatment Manufacturers


• Tendinitis Treatment Suppliers


• Medical Research Laboratories


• Research and Development (R&D) Companies


• Market Research and Consulting Service Providers


• Potential Investors

Segments 

The Americas & Europe tendinitis treatment market is segmented on the basis of type, treatment, and end user.

On the basis of type, the market is segmented into Achilles tendinitis, supraspinatus tendinitis, tennis or golfer's elbow, De Quervain's tenosynovitis, and others.

On the basis of treatment, the market is segmented into diagnosis, therapy, shock wave therapy or surgery, medical devices, devices, and others.

Diagnosis is further segmented into physical examination, imaging tests, ultrasound, Magnetic Resonance Imaging (MRI) Scans, and others.

Therapy is further segmented into non-pharmacological and pharmacological therapy. Non-pharmacological therapy includes rest therapy, heat & cold therapy, occupational therapy, physical therapy, and others. Pharmacological therapy includes OTC drugs or pain relievers, corticosteroids injections, platelet-rich plasma (PRP), and others.

Medical devices segment is further segmented mechanical band, support tape, pre-cut strips, continuous rolls, and others.

On the basis of end user, the market is segmented into hospitals & clinics, medical research centers, academic institutes, and others.

Regional Analysis of the Americas & Europe Tendinitis Treatment Market   

America is the largest market for tendinitis treatment owing to an increasing demand for new treatment options for tendinitis, and rising prevalence of sport injuries and disease such as arthritis. Furthermore, increasing number of sport injuries also influence the growth of the market. Sports medicine, is now gaining roots in the developing, and the developed regions of America. In America, North America captures the largest share in the tendinitis treatment market. 

According to the Center for Disease Control and Prevention, an estimated 78 million i.e. 26% of the U.S. adults aged 18 years or older are projected to have doctor-diagnosed arthritis by 2040. Additionally, the prevalence of tendinitis among athletes is found to be increasing from last few years in the U.S.

In Europe, the prevalence of diabetes and rheumatoid arthritis is on the rise. Furthermore, availability of funds for research and development activities in medical devices enhance the demand for technologically advanced devices for the diagnosis for tendinitis. Diabetes is one to the major risk factors for tendinitis. According to the report published by World Health Organization (WHO) in 2015, over 60 million people were suffering from diabetes in the European Region. Furthermore, lifestyle changes and lack of physical activity also influence the growth of this market in Europe. In Europe, Western European captures the largest share with German in leading position.Recent DevelopmentNovember 2023Camber Pharmaceuticals expands its product portfolio with the inclusion of Naproxen Oral Suspension, which is indicated for treating the signs and symptoms of tendinitis. Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that works by reducing inflammation and pain.Hyloris Pharmaceuticals announces that it has received FDA approval for its new drug, HY01, for the treatment of chronic tendinitis. HY01 is a hyaluronic acid (HA) injection that works by lubricating and cushioning the tendons.Ortho Clinical Diagnostics announces that it has launched a new test, the Ortho Clinical Diagnostics Tendinitis Panel, which can be used to diagnose and monitor tendinitis. The test measures the levels of three proteins that are involved in the development of tendinitis.October 2023A new study published in the journal Orthopaedics & Sports Physical Therapy finds that a combination of physical therapy and platelet-rich plasma (PRP) injections is effective in reducing pain and improving function in patients with tendinitis. PRP is a blood product that contains high concentrations of platelets, which are cells that play a role in healing.Another study published in the journal Pain Physician finds that a new type of corticosteroid injection, called triamcinolone acetonide microparticles (TA microparticles), is effective in reducing pain and improving function in patients with chronic tendinitis. TA microparticles are a long-acting form of corticosteroid that is released slowly over time.September 2023The American Academy of Orthopaedic Surgeons (AAOS) releases a new clinical practice guideline for the management of tendinitis. The guideline recommends a combination of physical therapy, NSAIDs, and other treatments, such as corticosteroid injections or PRP injections, depending on the severity of the condition.The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awards a grant to a team of researchers at the University of California, San Francisco to develop a new type of stem cell therapy for tendinitis. The therapy involves injecting stem cells into the affected tendon to promote healing.

Key Findings:

• By type, Achilles tendinitis acquired the largest market share in 2016.


• By treatment, diagnosis accounted for the largest market share in 2016 and is valued at USD 1200 million.


• By end user, hospitals & clinics accounted for the largest market share of 41.8% in the Americas & Europe tendinitis market, in 2016.

Key Players in the Americas & Europe Tendinitis Treatment Market

Some of the key players in this market are Abbott (U.S.), Pfizer (U.S.), AstraZeneca (U.K), Bayer (Germany), Merck & Co. Inc. (Germany), GlaxoSmithKline plc (U.S.), Teva Pharmaceutical Industries (Israel), Boehringer Ingelheim Pharmaceuticals, Inc. (Germany), and others.